Serina Therapeutics (SER) SVP awarded 69,000 stock options at $2.76

Rhea-AI Filing Summary

Serina Therapeutics, Inc. reported that senior vice president of CMC & Formulation Tenjarla Srini received a grant of stock options on common stock. The award covers 69,000 stock options with an exercise price of $2.76 per share, dated February 3, 2026, held as direct ownership.

These options vest over time: 12/48ths of the shares vest twelve months after the vesting commencement date, and the remaining 1/48th vests on the same calendar day of each following month until fully vested. Following this grant, Srini beneficially owns 69,000 derivative securities in the form of these options.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Tenjarla Srini

Role SVP, CMC & Formulation

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	69,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 69,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tenjarla Srini

(Last) (First) (Middle)

601 GENOME WAY, SUITE 2001

(Street)

HUNTSVILLE AL 35806

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Serina Therapeutics, Inc. [ SER ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CMC & Formulation

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.76	02/03/2026		A		69,000		(1)	02/03/2036	Common Stock	69,000	$0	69,000	D

Explanation of Responses:

1. Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested.

Remarks:

	/s/ Srini Tenjarla	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Serina Therapeutics (SER) report for Tenjarla Srini?

Serina Therapeutics reported that SVP CMC & Formulation Tenjarla Srini received a grant of 69,000 stock options on February 3, 2026. These options give the right to buy Serina common stock at a fixed exercise price of $2.76 per share.

What are the key terms of the 69,000 stock options granted at Serina Therapeutics (SER)?

The grant covers 69,000 stock options with a $2.76 exercise price, dated February 3, 2026. The options are held as direct ownership and represent derivative securities linked to Serina common stock, giving the holder potential future equity exposure if exercised.

How do the Serina Therapeutics (SER) options granted to Tenjarla Srini vest over time?

The options vest gradually: 12/48ths of the shares vest twelve months after the vesting commencement date. The remaining shares vest at 1/48th each month on the same calendar day thereafter, continuing until all 69,000 options are fully vested under the schedule.

What is the ownership status after the reported Form 4 transaction at Serina Therapeutics (SER)?

After the transaction, Tenjarla Srini beneficially owns 69,000 derivative securities in the form of stock options. The Form 4 notes this as direct ownership, meaning the options are held directly rather than through an intermediary entity or indirect structure.

Does the Form 4 for Serina Therapeutics (SER) show a purchase or sale of common stock?

The Form 4 does not show a common stock purchase or sale; it reports a grant of stock options. The transaction code is “A” for acquisition, reflecting an option award rather than an open-market buy or sell of Serina common shares.

What does transaction code "A" mean in the Serina Therapeutics (SER) Form 4?

Transaction code “A” on the Form 4 indicates a grant, award, or other acquisition of derivative securities. In this case, it records the award of 69,000 stock options to Tenjarla Srini, rather than a market transaction in existing Serina Therapeutics shares.